國立虎尾科技大學 |

Polymyxin Antibiotics: From Laboratory Bench to Bedside

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Polymyxin Antibiotics: From Laboratory Bench to Bedside/ edited by Jian Li, Roger L. Nation, Keith S. Kaye.
其他作者:	Li, Jian.
面頁冊數:	VIII, 366 p. 89 illus., 44 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Bacteriology. -
電子資源:	https://doi.org/10.1007/978-3-030-16373-0
ISBN:	9783030163730

Polymyxin Antibiotics: From Laboratory Bench to Bedside
Polymyxin Antibiotics: From Laboratory Bench to Bedside[electronic resource] /edited by Jian Li, Roger L. Nation, Keith S. Kaye. - 1st ed. 2019. - VIII, 366 p. 89 illus., 44 illus. in color.online resource. - Advances in Experimental Medicine and Biology,11450065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Overview -- Multidrug resistant Gram-negative pathogens: the urgent need for ‘old’ polymyxins -- Discovery, antibacterial spectrum and chemistry -- Mechanisms of antibacterial activity -- Mechanisms of resistance -- Bioanalysis and stability of polymyxins -- In vitro pharmacodynamics and PK/PD in animals -- Antibacterial susceptibility breakpoints -- Labeling of parenteral products of colistin methanesulfonate -- Meta-analysis of polymyxin use in patients -- Clinical use of colistin -- Clinical use of polymyxin B -- Pharmacokinetics, pharmacodynamics, toxicodynamics and dosing recommendations -- Rational combinations with other antibiotics -- Toxicities in patients: management and mechanisms -- Antiendotoxin effect -- Discovery of novel polymyxin-like antibiotics -- Conclusion.

This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field. It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research. This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ‘superbugs’.

ISBN: 9783030163730

Standard No.: 10.1007/978-3-030-16373-0doiSubjects--Topical Terms:

668505
Bacteriology.

LC Class. No.: QR74.8-99.5

Dewey Class. No.: 579.3

Polymyxin Antibiotics: From Laboratory Bench to Bedside
LDR:04225nam a22003975i 4500 001 1014732
003 DE-He213
005 20200703023510.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030163730 $9 978-3-030-16373-0
024 7 $a 10.1007/978-3-030-16373-0 $2 doi
035 $a 978-3-030-16373-0
050 4 $a QR74.8-99.5
072 7 $a PSGD $2 bicssc
072 7 $a SCI006000 $2 bisacsh
072 7 $a PSG $2 thema
082 0 4 $a 579.3 $2 23
245 1 0 $a Polymyxin Antibiotics: From Laboratory Bench to Bedside $h [electronic resource] / $c edited by Jian Li, Roger L. Nation, Keith S. Kaye.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VIII, 366 p. 89 illus., 44 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1145
505 0 $a Overview -- Multidrug resistant Gram-negative pathogens: the urgent need for ‘old’ polymyxins -- Discovery, antibacterial spectrum and chemistry -- Mechanisms of antibacterial activity -- Mechanisms of resistance -- Bioanalysis and stability of polymyxins -- In vitro pharmacodynamics and PK/PD in animals -- Antibacterial susceptibility breakpoints -- Labeling of parenteral products of colistin methanesulfonate -- Meta-analysis of polymyxin use in patients -- Clinical use of colistin -- Clinical use of polymyxin B -- Pharmacokinetics, pharmacodynamics, toxicodynamics and dosing recommendations -- Rational combinations with other antibiotics -- Toxicities in patients: management and mechanisms -- Antiendotoxin effect -- Discovery of novel polymyxin-like antibiotics -- Conclusion.
520 $a This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field. It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research. This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ‘superbugs’.
650 0 $a Bacteriology. $3 668505
650 0 $a Pharmacotherapy. $3 973587
650 0 $a Drug resistance. $3 872072
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Li, Jian. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 815846
700 1 $a Nation, Roger L. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1229026
700 1 $a Kaye, Keith S. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1229027
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030163716
776 0 8 $i Printed edition: $z 9783030163723
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-16373-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)